Innovation-led biopharma startup Lamark Biotech raises Rs 6.5 crore in funding

Lamark Biotech, an innovation-led biopharma startup, raised Rs 6.5 crore in a pre-Series A funding round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Dr. Vinayender Tulla, Dr. Nita Roy, and Venkataraman KNK, domain experts of IAN’s angel investors.

Founded in 2018 by Dr. Vaibhav Bhatia, a entrepreneur and Biochemist by training, Lamark Biotech is reimagining drug delivery for chronic and life-altering diseases. Its proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. Lamark addresses a critical gap in the biologics ecosystem: reducing the cold-chain dependency.

“We’re accelerating our thermostable insulin program and expanding ProteoStrong to more critical therapeutics using this resource. Our priority is clear- make safe and high-efficacy biologics for all. We believe, ‘if it is not accessible, it not a medicine’,” said Vaibhav Bhatia, who is also the CEO of the company.

Padmaja Ruparel, Co-founder, IAN Group, said, “Investment in Lamark represents IAN’s investment strategy to invest and grow innovations that solve real problems. The solution is critical in low-resource environments, with Lamark's thermostable biologics which can make critical treatments accessible at a low cost for millions of people, both in India and globally.”

The Ahmedabad-based startup, leveraging R&D base of Venture Center, NCL- innovation park in Pune, is advancing a new class of temperature-resilient biologics that retain potency across extreme conditions, ideal for underserved regions where cold storage infrastructure is limited.

With its lead program, InsulinStrong, Lamark is targeting the Rs 4,000 crore Indian insulin market and intends to expand across Southeast Asia and the UAE. expanding its platform into diabetic eye disease and cancer immunotherapy.

In the next 24 months, it plans to file new international patents, begin early clinical trials, and build partnerships with pharma companies, CDMOs, and global health agencies.